Semaglutide and muscle loss: what health plans need to know

Semaglutide has transformed the obesity treatment landscape. Originally approved for diabetes, it is now one of the most widely prescribed GLP-1 medications for weight management, often better known by brand names such as Ozempic, Wegovy, and Rybelsus.

With outcomes that can include meaningful total body weight loss and improved cardiometabolic markers, it is no surprise that health plans are rapidly expanding coverage.² Semaglutide offers a powerful new lever to address obesity-related costs and long-term risk.

But there is a less visible risk emerging in the data, one that could undermine outcomes, raise musculoskeletal risk, and reduce long-term value for health plans.

Research suggests that up to 39% of weight lost during semaglutide treatment may come from lean mass.¹

That is not a cosmetic concern. Lean-mass loss can affect metabolism, injury risk, physical function, and long-term independence. Without a strategy to help protect lean mass, health plans may find themselves covering a second wave of care, including falls, joint pain, repeat prescribing pressure, and downstream musculoskeletal claims.

How semaglutide can lead to muscle loss

Semaglutide mimics a hormone called GLP-1, which helps regulate appetite and digestion. It works by:

• slowing gastric emptying
• suppressing hunger
• reducing overall food intake

This can produce effective, sustained weight loss. But unless that weight loss is paired with support for movement and muscle-supportive nutrition, the body may lose both fat and metabolically active tissue, including lean mass.¹

That risk may be higher in members who begin treatment from a low-activity baseline. Fewer than 1 in 4 U.S. adults meet CDC physical activity guidelines, which means many semaglutide users may already begin treatment without the strength and activity habits that help preserve lean mass.³

Why lean muscle matters (and what happens when it’s lost)

Muscle is not optional. It is a critical driver of physical health and long-term function. Muscle supports:

• joint stability by reducing stress on knees, hips, and spine⁴
• balance and coordination that help reduce fall risk⁵
• metabolic efficiency, including energy use at rest⁶
• functional independence in daily life⁷

When lean mass declines, members become more vulnerable to chronic pain⁷, balance issues and fall-related injuries⁵, slower recovery, and functional decline, even as weight decreases.

This effect can be even more pronounced in older adults, desk workers, and anyone managing chronic musculoskeletal or metabolic conditions. Many of these people are also strong candidates for GLP-1 treatment.

Why muscle loss does not show up clearly in claims data

One of the biggest challenges in managing semaglutide-related risk is visibility. Lean-mass loss is not usually coded as a diagnosis. There is often no line item in a pharmacy claim or routine lab panel that tells you a member is physically weaker than before.

But the downstream effects are real.

Research links sarcopenia with:

• up to 33% of chronic pain cases in older adults⁷
• a 60% higher risk of falls⁵
• a 2.5x higher disability risk when combined with obesity⁸

These outcomes do not usually appear immediately after a member starts semaglutide. They surface later, often in the form of fall-related injuries, joint pain, therapy referrals, orthopedic utilization, or other musculoskeletal issues.

Research also suggests that as much as two-thirds of weight lost on GLP-1s may be regained after discontinuation.⁹ When lean mass is lost during treatment, the body may be less equipped to maintain results over time.

Sarcopenia adds nearly $900 in excess healthcare costs per employee annually.¹⁰ That means short-term weight loss can mask longer-term risk when lean mass is not protected.

The semaglutide cost curve does not always end at the pharmacy

Most cost analyses of GLP-1 treatment focus on pharmacy spend. WTW has estimated that GLP-1s can cost employers up to $10,000 per member annually.¹¹

But semaglutide’s real cost exposure expands if treatment is not paired with structured support:

• weight is lost, but so can functional resilience
• members may become less physically capable as lean mass declines
• musculoskeletal issues can emerge later, sometimes requiring more costly intervention

Plans that focus only on early weight-loss outcomes risk missing a second cost curve driven by pain, falls, functional decline, and lower long-term durability.

How to help protect lean mass during semaglutide treatment

Semaglutide-related weight loss does not automatically protect lean mass. Without the right support, inactivity and reduced intake can make lean-mass loss more likely.

Health plans and employers should look for structured support that can provide:

• early movement readiness support to build baseline strength
• ongoing strength-focused activity support during medication use
• post-discontinuation support to help maintain outcomes
• real-time visibility into activity, function, and progress
• reporting tied to outcomes beyond engagement alone

This kind of wraparound support improves the odds of more sustainable long-term success.

Pulse, the cardiometabolic pillar of the AI Care Platform, is designed to support GLP-1 users through continuous lifestyle support across movement, nutrition guidance, and daily habits. Pulse is built to address the parts of the journey medication alone does not cover.

Pulse supports semaglutide users to change habits for good

Pulse supports people managing blood pressure, blood sugar, cholesterol, weight, and GLP-1 use through continuous lifestyle support. For people using semaglutide, Pulse is built to address what medication alone does not: lean-mass preservation, strength-building support, nutrition guidance, and the day-to-day habits that help results last.

Pulse combines Phoenix, Sword Health’s AI Care Specialist, with guidance from a Health Specialist and connected devices that bring objective health data into each interaction. Members receive personalized support across movement, nutrition, and daily habits, with guidance that adapts over time to what is actually working for them.

What progress can look like with Pulse

Pulse supports GLP-1 users with continuous lifestyle support built around movement, nutrition guidance, and daily habits. In Pulse:

• 83% of members report feeling better or much better¹²
• 51% of members with low physical activity at baseline reached the World Health Organization recommended activity threshold after 27 days of Pulse sessions¹³

These signals do not prove every downstream financial outcome on their own. But they do show the kind of sustained engagement plans need if they want semaglutide strategies to produce more durable value over time

Future-proof your semaglutide outcomes with Pulse

emaglutide is a powerful tool in the fight against obesity, but it is only one part of an effective GLP-1 strategy. Without structured support, weight loss can come at the cost of lean mass, raising musculoskeletal risk and increasing downstream exposure for health plans.

Structured support can help reduce the hidden cycle of pain, repeat prescribing pressure, and lower long-term value. Pulse is designed to close that gap with support that extends beyond the prescription itself.

With continuous support across strength, nutrition guidance, and daily habits, Pulse helps members protect lean mass and build routines that make semaglutide results more sustainable.